CymaBay Therapeutics (CBAY) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
CymaBay Therapeutic (CBAY) PT Raised to $13 at Piper Jaffray
November 9, 2017 7:54 AM ESTPiper Jaffray raised its price target on CymaBay Therapeutic (NASDAQ: CBAY) to $13.00 (from $12.00) while maintaining a Overweight rating.
Analyst Edward A. Tenthoff notes the company ended the quarter with $102.2 million in cash to advanced Seladelpar in PBC and NASH.
... More